Results 221 to 230 of about 541,983 (306)

The Impact of Nonsteroidal Anti‐Inflammatory Drugs on Radiographic Spinal Progression in Patients With Axial Spondyloarthritis: 10‐Year Results From an Inception Cohort

open access: yesArthritis &Rheumatology, EarlyView.
Objective This study aims to investigate the impact of nonsteroidal anti‐inflammatory drug (NSAID) intake on radiographic spinal progression in axial spondyloarthritis (axSpA), considering different NSAID types (COX‐2 inhibitors [COX2i] and nonselective NSAIDs [ns‐NSAIDs]) and disease subgroups (radiographic [r‐axSpA] and nonradiographic [nr‐axSpA ...
Murat Torgutalp   +8 more
wiley   +1 more source

Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis

open access: yesArthritis &Rheumatology, Accepted Article.
Background Transition from long‐term denosumab to PTH‐analogs or romosozumab might expose patients to the risk of the so‐called rebound phenomenon. Adding romosozumab to denosumab might represent an option in patients experiencing a fracture while on denosumab.
Giovanni Adami   +10 more
wiley   +1 more source

Per‐ and polyfluoroalkyl substances and hand osteoarthritis: data from the Osteoarthritis Initiative

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To explore whether biological levels of specific per‐ and polyfluoroalkyl substances (PFAS) and a mixture of PFAS – reflecting the overall effect and accounting for correlations among each PFAS – relate to incident hand osteoarthritis (HOA) and progression.
Jeffrey B. Driban   +14 more
wiley   +1 more source

Long‐Term Outcomes of Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation for Systemic Sclerosis Patients with Impaired Cardiac Function

open access: yesArthritis &Rheumatology, Accepted Article.
Objective High intensity conditioning autologous hematopoietic stem cell transplantation (AHSCT) is standard of care for patients with advanced SSc. The role of reduced intensity conditioning (RIC) prior to AHSCT in this population remains unclear. We conducted this study to determine the long‐term outcomes of RIC AHSCT in SSc patients with cardiac ...
Yonatan Lean   +4 more
wiley   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: the Randomized, Phase 3, TULIP‐SC Study

open access: yesArthritis &Rheumatology, Accepted Article.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate‐to‐severe SLE activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly for 52 weeks (1:1 ...
Susan Manzi   +12 more
wiley   +1 more source

Performance of the Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) Calculator in Rheumatoid Arthritis

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Evaluate performance of the Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) calculator in rheumatoid arthritis (RA). Methods Patients with RA were matched up to 10 controls on age, sex, and enrollment year using national Veterans Health Administration (VHA), Medicare, and National Death Index data (2006‐2020).
Tate M. Johnson   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy